<DOC>
	<DOCNO>NCT01302860</DOCNO>
	<brief_summary>This trial ass safety , efficacy tolerability ACZ885 patient age 4 year young cryopyrin associate periodic syndrome ( CAPS )</brief_summary>
	<brief_title>Efficacy , Safety Tolerability ACZ885 Pediatric Patients With Following Cryopyrin-associated Periodic Syndromes : Familial Cold Autoinflammatory Syndrome , Muckle-Wells Syndrome , Neonatal Onset Multisystem Inflammatory Disease</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cryopyrin-Associated Periodic Syndromes</mesh_term>
	<mesh_term>Cellulitis</mesh_term>
	<mesh_term>Eosinophilia</mesh_term>
	<criteria>1 . Male female patient 28 day 60 month age time screen visit . 2 . Body weight &gt; = 2.5 kg . 3 . Parent legal guardian 's write informed consent require assessment perform patient . 4 . At study entry , patient clinical diagnosis FCAS , MWS , NOMID symptoms require pharmacological intervention . Prior agreement Investigator Novartis study eligibility require patient molecular diagnosis NALP3 mutation available ( either test perform , test perform negative ) upon study entry . For patient molecularly test NALP3 mutation , molecular testing perform course study . 5 . For patient treated IL1 blocking agent ( i.e . anakinra , rilonacept ) , treatment discontinue prior baseline visit patient must demonstrate active disease prior treatment . 6 . Patients schedule receive immunization , accord local vaccination guideline , inactivated vaccine must willing participate assessment schedule vaccinate patient . 1 . Preterm neonates , Investigator 's judgment , participation study deem appropriate . 2 . History recurrent and/or evidence active bacterial , fungal , viral infection ( include HIV ) . 3 . Patients immunodeficiency treatment immunosuppressive drug . 4 . Live vaccination within &lt; = 3 month prior screen . No live vaccination allow throughout course study 3 month follow last dose . 5 . Patients increase risk tuberculosis ( TB ) infection accord follow risk factor : Patients recent close contact person know active pulmonary TB disease Foreignborn patient country high prevalence tuberculosis Patients recent tuberculosis infection ( include child &gt; 6 month positive PPD test [ define induration least 10mm ] ) Patients endstage renal disease Patients diabetes mellitus Patients receive immunosuppressive therapy Patients hematologic cancer . 6 . Participation another trial within last 30 day 5 halflives investigational compound ( whichever longer ) . 7 . Familial social condition render regular medical assessment possible . 8 . Pediatric patient neutropenia ( absolute neutrophil count [ ANC ] &lt; 1.5 x 10 9th/l ) Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>60 Months</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cryopyrin-associated periodic syndrome ( CAPS )</keyword>
	<keyword>Familial Cold Autoinflammatory Syndrome ( FCAS )</keyword>
	<keyword>Muckle-Wells Syndrome ( MWS ) Neonatal Onset Multisystem Inflammatory Disease ( NOMID )</keyword>
	<keyword>child</keyword>
	<keyword>systemic autoinflammatory disease</keyword>
	<keyword>CIAS-1 gene</keyword>
	<keyword>NALP-3</keyword>
	<keyword>NLRP3</keyword>
	<keyword>ACZ885</keyword>
	<keyword>Ilaris</keyword>
	<keyword>human monoclonal anti-human interleukin-1 beta ( IL-beta )</keyword>
	<keyword>antibody</keyword>
	<keyword>autosomal dominant</keyword>
	<keyword>familial autoinflammatory syndrome</keyword>
</DOC>